VAXXEL
Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.
VAXXEL
Industry:
Pharmaceutical
Founded:
2019-09-01
Address:
Villeurbanne, Rhone-Alpes, France
Country:
France
Website Url:
http://www.vaxxel.fr
Total Employee:
11+
Status:
Active
Total Funding:
1.2 M EUR
Technology used in webpage:
COVID-19 IONOS
Similar Organizations
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Clario
Clario delivers the endpoint technology solutions for clinical trials.
Farmazon
Farmazon is an online shopping platform that provides medical, dietary supplements and health products for pharmacists.
Chalice Brands
Chalice Brands is a fast growing company and leading cannabis oil solutions company built around recognized brands.
Navinata Health
Navinata Health is conveniently educating today's busy Physicians about innovative life-saving Therapies
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Current Employees Featured
Denis Cavert Co-Founder & CEO @ Vaxxel
Co-Founder & CEO
2019-09-01
Founder
Investors List
Bpifrance
Bpifrance investment in Seed Round - Vaxxel
Angels Santé
Angels Santé investment in Seed Round - Vaxxel
Femmes Business Angels
Femmes Business Angels investment in Seed Round - Vaxxel
Official Site Inspections
http://www.vaxxel.fr Semrush global rank: 11.3 M Semrush visits lastest month: 166
- Host name: 217-160-0-151.elastic-ssl.ui-r.com
- IP address: 217.160.0.151
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Vaxxel"
Vaxxel — Centre International de Recherche en Infectiologie
Vaxxel develops innovative and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumoviruses. The objective of Vaxxel’s technology …See details»
Vaxxel - LinkedIn
Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava...See details»
Vaxxel - Crunchbase Company Profile & Funding
Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and …See details»
Vaxxel, nouvel acteur des vaccins contre le …
Oct 8, 2019 · Vaxxel a breveté le métapneumovirus isolé et génétiquement modifié dans une version non pathogène. Cette plate-forme, baptisée « Metavac », a fait sa preuve de concept sur l'animal.See details»
VAXXEL - Societe.com
VAXXEL, société par actions simplifiée, immatriculée sous le SIREN 854075678, est active depuis 5 ans. Installée à VILLEURBANNE (69100), elle est spécialisée dans le secteur …See details»
Vaxxel Company Profile 2024: Valuation, Funding & Investors
The company specializes in developing live-attenuated vaccines against bronchiolitis and pneumonia and in particular against human metapneumovirus and against the human …See details»
Vaxxel - EU-Startups
Villeurbanne. Tags: Pharmaceutical. Total Funding: Between €1 million-€ 2.5 million. Founded: 2019. Website: https://vaxxel.fr. You're a corporate or investor and looking for startups that are …See details»
Vaxxel - The Pharmaletter
"Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac vaccine platform. This platform has been funded and …See details»
Réseau SATT
Récompensée lors du concours i-Lab 2019 pour son engagement dans la lutte contre les infections respiratoires à pneumovirus, la startup VAXXEL, incubée à PULSALYS et issue du …See details»
Vaxxel raises 1.2m to fund the development of its intranasal …
Mar 18, 2022 · Vaxxel develops two vaccine candidates against respiratory infections: a monovalent vaccine against human Metapneumovirus (hMPV), and a bivalent vaccine against …See details»
Réseau SATT
Vaxxel, startup lyonnaise dédiée aux vaccins contre les infections virales respiratoires, annonce l’acquisition de la lignée cellulaire DuckCelt®-T17 auprès de Transgene, au terme d’un …See details»
Vaxxel lève 1,2 million pour préparer la phase clinique ... - Les Echos
Mar 18, 2022 · La start-up lyonnaise avance dans le développement de ses vaccins contre les pneumovirus, responsables d'infections respiratoires aiguës chez les enfants de moins de 5 …See details»
Vaxxel lève 1,2 million d'euros pour accélérer le développement …
Mar 21, 2022 · D’après son président, Vaxxel, qui a déposé un brevet pour protéger sa technologie, se positionne sur un marché supérieur à 5 milliards d’euros.See details»
Vaxxel acquires Transgene's DuckCelt®-T17 cell line to develop ...
May 5, 2020 · Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt®-T17 cell line. The …See details»
Vaxxel Acquires Transgene's DuckCelt-T17 Cell Line | Reuters
May 4 (Reuters) - TRANSGENE SA: * VAXXEL ACQUIRES TRANSGENE'S DUCKCELT®-T17 CELL LINE TO DEVELOP INDUSTRIAL-SCALE VACCINES AGAINST RESPIRATORY …See details»
Vaxxel raises EUR 1.2m to fund the development of its intranasal ...
Mar 18, 2022 · Vaxxel , a French start-up developing vaccines against respiratory viral infections, announces it has raised €1.2 million funding to support the development of the first intranasal …See details»
Vaxxel acquiert la lignée cellulaire DuckCelt®-T17 de Transgene …
Vaxxel développe deux vaccins contre des infections respiratoires : l’un, monovalent ontre le Metapneumovirus humain (hMPV), et l’autre ivalent ontre hMPV et ontre le Virus Respiratoire …See details»
Vaxxel acquires Transgene's DuckCelt®-T17 cell line to develop ...
Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac® vaccine platform. This platform has been funded and …See details»
Vaxxel at BIO2022 - LinkedIn
May 16, 2022 · Vaxxel, a French biotech company developing the first intranasal vaccine against bronchioltis and viral pneumonia caused by HMPV and RSV is proud to announce its …See details»
Vaxxel acquires Transgene's DuckCelt®-T17 cell line to develop ...
Vaxxel’s live attenuated vaccine candidates are based on two proprietary technologies: Metavac®, an hMPV seed attenuated through reverse genetic, and DuckCelt®-T17, an avian …See details»